Qube Research & Technologies LTD Clovis Oncology, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.05 - $1.3 $404 - $10,527	-8,098 Reduced 40.33%	11,980 $0
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.85 $21,081 - $57,222	20,078 New	20,078 $24,000
Q2 2022 Aug 15, 2022	SELL	$0.63 - $2.96 $309,352 - $1.45 Million	-491,036 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$1.43 - $3.14 $622,581 - $1.37 Million	435,372 Added 782.14%	491,036 $992,000
Q4 2021 Feb 01, 2022	BUY	$2.7 - $4.76 $150,292 - $264,960	55,664 New	55,664 $151,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.